Official feed of NICE - National Institute for Health and Care Excellence. We produce evidence-based health and social care guidance. Tweets by the comms team.
People with a rare genetic disease could soon benefit from a new treatment option.
Our independent committee has recommended belzutifan for treating tumours associated with von Hippel-Lindau disease.
Learn more:
#NICENews
📣
#HETT24
Session: 'Assessing the Expansion of Private Health with Apps and Wearables - What Impact do They Have on Patient Outlook on Health?' Explore the impact of digital health tools & how they relieve system pressure. Secure your pass ➡️
@NICEComms
"It's recognizing it's a fairly early stage for us, we don't have all the answers, but we wanted to put something out there to signify the importance of AI."
— Nick Crabb, discusses the NICE position statement on the use of
#AI
in evidence generation.
#CDA_AMC
@NICEComms
🔊 Listen to the latest news bulletin from National
#Health
Executive ⬇️
🚨 NHS mental health: Charity calls for increased
#prevention
funding
🚨 NICE makes two landmark approvals
🚨
#NHS
CEO Amanda Pritchard makes armed forces pledge
For more details on all our stories, check
Join us online to hear from NICE’s Deputy CEO, Jonathan Benger, on how we are refining our HST programme.
Learn how these changes will enhance transparency, consistency, and access to treatments for very
#RareDiseases
.
Register here:
⏰
#NICEConf2025
early bird discount ends 15 September.
The conference will bring frontline staff and leaders from health and care together with the life sciences, healthtech and digital sectors.
📅 Register now to join us in Manchester on 27 March:
People with advanced
#thyroidcancer
could be set to benefit from a new treatment recommended today.
Our independent advisory committee has recommended selpercatinib in final draft guidance.
Learn more:
#NICENews
First treatment for marginal zone lymphoma after anti-CD20-based treatment, recommended by NICE in final guidance.
Zanubrutinib is a pill treatment, providing a more convenient option than current standard care.
Find out more:
Around 330,000 adults with overactive bladder syndrome could be set to benefit after we recommended Vibegron, a new daily pill, in final guidance today.
Find out more⤵️
#NICENews
"It feels like you've given me a new pancreas."
Diagnosed with
#T1Diabetes
at 22, Ammaarah had constant migraines and disrupted sleep.
Life changed when she received a NICE-recommended hybrid closed loop system, often called an 'artificial pancreas.'
🔗
Health and care professionals, stay updated with NICE's latest guidelines via our new WhatsApp updates channel.
📲 On mobile? Join here:
🖥 On desktop? Scan the QR code in the video
🔔Once subscribed hit the bell to stay notified.
We’re inviting healthtech and pharmaceutical developers to join us for a free NICE Advice webinar.
Learn about our guidance topic priorities for 2024/25 and beyond, and the implications for the life sciences sector⬇️
Join Sharmila Nebhrajani OBE, Chair of NICE, as she delves into the monumental changes ahead for healthcare. From tackling the 'postcode lottery' to embracing cutting-edge digital technologies and AI....
Read more! 👇